• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Amphastar Pharmaceuticals Inc.

    3/26/26 3:46:08 PM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMPH alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 5)


    Amphastar Pharmaceuticals Inc

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)




    03209R103

    (CUSIP Number)
    03/13/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    03209R103


    1Names of Reporting Persons

    The Vanguard Group
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    IA

    Comment for Type of Reporting Person:   On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Amphastar Pharmaceuticals Inc
    (b)Address of issuer's principal executive offices:

    11570 6th Street, Rancho Cucamonga, CA, 91730
    Item 2. 
    (a)Name of person filing:

    The Vanguard Group
    (b)Address or principal business office or, if none, residence:

    100 Vanguard Blvd.,, Malvern, PA, 19355
    (c)Citizenship:

    PA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    0
    (b)Percent of class:

    0  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Vanguard Group, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.No one other person's interest in the securities reported herein is more than 5%.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Vanguard Group
     
    Signature:Ashley Grim
    Name/Title:Head of Global Fund Administration
    Date:03/26/2026
    Get the next $AMPH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMPH

    DatePrice TargetRatingAnalyst
    12/9/2025$30.00Equal Weight
    Barclays
    8/12/2025$36.00Hold → Buy
    Needham
    5/12/2025$30.00Overweight → Neutral
    Analyst
    2/4/2025$66.00 → $36.00Overweight → Neutral
    Piper Sandler
    11/22/2024$55.00Equal Weight
    Wells Fargo
    3/5/2024$60.00Overweight
    JP Morgan
    11/17/2023$63.00Neutral
    BofA Securities
    7/25/2023$70.00Buy
    Jefferies
    More analyst ratings

    $AMPH
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Amphastar Pharmaceuticals Inc.

    SCHEDULE 13G/A - Amphastar Pharmaceuticals, Inc. (0001297184) (Subject)

    3/26/26 3:46:08 PM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amphastar Pharmaceuticals Inc. filed SEC Form 8-K: Other Events

    8-K - Amphastar Pharmaceuticals, Inc. (0001297184) (Filer)

    3/16/26 6:00:25 AM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amphastar Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Amphastar Pharmaceuticals, Inc. (0001297184) (Filer)

    3/6/26 4:17:52 PM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP CORP ADMIN CENTER Liawatidewi Yakob covered exercise/tax liability with 1,033 shares, decreasing direct ownership by 0.84% to 121,892 units (SEC Form 4)

    4 - Amphastar Pharmaceuticals, Inc. (0001297184) (Issuer)

    3/17/26 8:17:50 PM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SENIOR EVP, PRODUCTION CENTER Zhou Rong covered exercise/tax liability with 1,225 shares, decreasing direct ownership by 0.71% to 171,554 units (SEC Form 4)

    4 - Amphastar Pharmaceuticals, Inc. (0001297184) (Issuer)

    3/17/26 6:16:22 PM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CFO, EVP & TREASURER Peters William J covered exercise/tax liability with 1,973 shares, decreasing direct ownership by 1% to 175,063 units (SEC Form 4)

    4 - Amphastar Pharmaceuticals, Inc. (0001297184) (Issuer)

    3/17/26 6:14:22 PM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Amphastar Pharmaceuticals with a new price target

    Barclays initiated coverage of Amphastar Pharmaceuticals with a rating of Equal Weight and set a new price target of $30.00

    12/9/25 8:42:43 AM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amphastar Pharmaceuticals upgraded by Needham with a new price target

    Needham upgraded Amphastar Pharmaceuticals from Hold to Buy and set a new price target of $36.00

    8/12/25 7:45:35 AM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amphastar Pharmaceuticals downgraded by Analyst with a new price target

    Analyst downgraded Amphastar Pharmaceuticals from Overweight to Neutral and set a new price target of $30.00

    5/12/25 8:19:14 AM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMPH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $AMPH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    Amphastar Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

    RANCHO CUCAMONGA, CA / ACCESSWIRE / January 8, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15th, 2025, at 11:15 am PST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Comp

    1/8/25 6:00:00 AM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amphastar Pharmaceuticals to Present at the 36th Annual Piper Sandler Healthcare Conference

    RANCHO CUCAMONGA, CA / ACCESSWIRE / November 26, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4th, 2024 at 11:30 am EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalatio

    11/26/24 4:05:00 PM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference

    RANCHO CUCAMONGA, CA / ACCESSWIRE / November 13, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will participate in an Analyst-Moderated fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 3:30 pm GMT. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalatio

    11/13/24 4:05:00 PM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for MEDROXYPROGESTERONE ACETATE issued to AMPHASTAR PHARMS INC

    Submission status for AMPHASTAR PHARMS INC's drug MEDROXYPROGESTERONE ACETATE (SUPPL-5) with active ingredient MEDROXYPROGESTERONE ACETATE has changed to 'Approval' on 01/25/2024. Application Category: ANDA, Application Number: 077334, Application Classification: Labeling

    1/26/24 4:40:02 AM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for CORTROSYN issued to AMPHASTAR PHARMS INC

    Submission status for AMPHASTAR PHARMS INC's drug CORTROSYN (SUPPL-33) with active ingredient COSYNTROPIN has changed to 'Approval' on 12/22/2023. Application Category: NDA, Application Number: 016750, Application Classification: Labeling

    12/27/23 4:38:39 AM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NALOXONE HYDROCHLORIDE issued to AMPHASTAR PHARMS INC

    Submission status for AMPHASTAR PHARMS INC's drug NALOXONE HYDROCHLORIDE (SUPPL-1) with active ingredient NALOXONE HYDROCHLORIDE has changed to 'Approval' on 06/29/2023. Application Category: NDA, Application Number: 208969, Application Classification: Labeling

    6/30/23 9:33:25 AM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMPH
    Financials

    Live finance-specific insights

    View All

    Amphastar Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

    RANCHO CUCAMONGA, CA / ACCESSWIRE / January 8, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15th, 2025, at 11:15 am PST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Comp

    1/8/25 6:00:00 AM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amphastar Pharmaceuticals to Present at the 36th Annual Piper Sandler Healthcare Conference

    RANCHO CUCAMONGA, CA / ACCESSWIRE / November 26, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4th, 2024 at 11:30 am EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalatio

    11/26/24 4:05:00 PM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference

    RANCHO CUCAMONGA, CA / ACCESSWIRE / November 13, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will participate in an Analyst-Moderated fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 3:30 pm GMT. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalatio

    11/13/24 4:05:00 PM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Amphastar Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Amphastar Pharmaceuticals, Inc. (0001297184) (Subject)

    3/6/24 10:23:26 AM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Amphastar Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Amphastar Pharmaceuticals, Inc. (0001297184) (Subject)

    2/13/24 4:58:53 PM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Amphastar Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Amphastar Pharmaceuticals, Inc. (0001297184) (Subject)

    2/9/24 5:21:50 PM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care